Coronavirus and Cancer Resources for Survivors
Cancer survivors have expressed concerns and questions about COVID-19, the coronavirus, and how they may be at higher risk due to their cancer history. Here are some resources about COVID-19 generally, and its impact for cancer survivors specifically. NCCS is seeking answers from public health experts on the coronavirus and its impact on cancer patients and survivors. Please leave a comment [...]
NCCS Submits Comments to House Energy and Commerce Committee on 21st Century Cures Legislation
The National Coalition for Cancer Survivorship (NCCS) submitted comments to the House Energy and Commerce Committee on its 21st Century…
The New Medicare Oncology Care Model Will Improve Quality of Care for Cancer Patients
The National Coalition for Cancer Survivorship (NCCS) applauds the release by the Centers for Medicare and Medicaid Services (CMS)…
NCCS Policy Comments: FDA’s Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)
NCCS submitted comments to the Food and Drug Administration (FDA) on the Draft Guidance: Framework for Regulatory Oversight of Laboratory…
NCCS Joins Colleagues in Submitting Comments to NIH on the Use of a Single Institutional Review Board for Multi-Site Research
Today, NCCS joined colleagues in the cancer community in submitting comments to the National Institutes of Health (NIH) on the Draft…
NCCS Joins Colleagues in Submitting Comments to HHS Regarding Proposed Rule on Notice of Benefit and Payment Parameters for 2016
In late December 2014, NCCS joined colleagues in the Cancer Leadership Council in submitting comments to the Department of Health and…
NCCS Joins Colleagues in Submitting Comments to National Association of Insurance Commissioners on the Health Benefit Plan Network Access and Adequacy Model Act
Last week, NCCS joined colleagues in the Cancer Leadership Council (CLC) in submitting comments to the National Association of Insurance…
NCCS Policy Comments: Recommending Cancer Survivorship as a Topic for FDA Patient-Focused Drug Development Meetings
Last week, NCCS submitted comments to the U.S. Food and Drug Administration (FDA) regarding the series of patient-focused drug development…
NCCS Offers Policy Comments: Strategies for Increasing Patient Participation in FDA Review Activities
The Food and Drug Administration Safety and Innovation Act (FDASIA) authorized a patient-focused drug development program, and in the…
NCCS Offers Comments to the Centers for Medicare and Medicaid Innovation on their proposed Oncology Care Model
Click here to view all of NCCS' policy comments.
Recently, NCCS submitted comments to the Center for Medicare and Medicaid Innovation…
NCCS and CLC Policy Comments: 2015 Physician Fee Schedule
Recently, NCCS joined colleagues in the Cancer Leadership Council (CLC) in submitting comments to the Centers for Medicare and Medicaid…